The incidence of hyperglycemia during the induction phase of chemotherapy in patients with acute lymphoblastic leukemia
نویسندگان
1 Assistant Professor, Pediatric Endocrinologist, The Clinical Research Development Unit of Amirkola Children's Hospital, Babol University of Medical Sciences, Babol, IR Iran.
2 Associated Professor, Pediatric Hematologist & Oncologist, Non-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, IR Iran.
3 Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
4 Student of Statistics (MSc), Department of Statistics, University of Mazandaran, Babolsar, IR Iran.
5 Associated Professor, Pediatric Hematologist & Oncologist, Non-Communicable Pediatric Diseases Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, IR Iran.
6 GP, Student Research Committee, Babol University of Medical Sciences, Babol, IR Iran.
7 GP, Student Research Committee, Babol University of Medical Sciences, Babol, IR Iran.
doi
10.18502/ijpho.v9i2.605چکیده
Background: Hyperglycemia is one of the most complications of corticosteroid and asparaginase during induction phase of chemotherapy in children suffering from acute lymphoblastic leukemia (ALL). This study was carried out to evaluate the incidence of hyperglycemia and associated risk factors during chemotherapy induction phase at Amirkola Children's Hospital. Materials and ...
